News|Articles|August 31, 2026

Dermatology Times Monthly FDA & Pipeline Review: August 2026

Author(s)Shannon Heaning, Content Associate

A twice-rejected melanoma immunotherapy finally won accelerated approval, acne's decades-long innovation drought moved a step closer to ending, and 2 rare, sun-triggered skin diseases picked up a deep-pocketed new sponsor.

Welcome to the Dermatology Times Monthly FDA & Pipeline Review, a recurring look at the regulatory actions and drug development milestones shaping dermatology practice. Each installment tracks approvals, filings, and clinical data readouts against what they mean for patient care, not just what made headlines.